Allist Pharmaceuticals

688578 · SSE STAR Market

Public Market Listing

688578SSE STAR Market

SSE STAR Market primary exchange listing

Live quotes, historical charts, and market capitalization for Allist Pharmaceuticals are available on Yahoo Finance.

View quote & market cap on Yahoo Finance ↗

External market data link · No third-party exchange redistribution

Assets

(4 total)
4Total Assets
0Approved
3Phase 3 / Filed
1Phase 1–2 / Early
1Diseases
Showing 4 of 4 assets
Target & Modality
Phase 3
EGFRSmall molecule
Non-Small Cell Lung Cancer
Phase 3
KRAS G12CSmall molecule
Non-Small Cell Lung Cancer
Phase 3
SHP2Small molecule
Non-Small Cell Lung Cancer
Phase 1
EGFRSmall molecule
Non-Small Cell Lung Cancer

Upcoming events

(9 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (2)
December 2026 (2)
FurmonertinibPhase 3Non-small Cell Lung Carcinoma
Est. primary completion 2026-12 · NCT04853342 · CT.gov ↗
What to watch
GlecirasibPhase 2KRAS P.G12C, Pancreatic Cancer, Solid Tumor
Est. primary completion 2026-12-31 · NCT06008288 · CT.gov ↗
What to watch
2027 (3)
March 2027 (1)
Glecirasib + SitneprotafibPhase 1/2KRAS P.G12C, Non-small Cell Lung Cancer, Colorectal Cancer, Pancreatic Ductal Carcinoma
Est. primary completion 2027-03 · NCT05288205 · CT.gov ↗
What to watch
August 2027 (1)
GlecirasibPhase 1/2Non-small Cell Lung Cancer
Est. primary completion 2027-08 · NCT05276726 · CT.gov ↗
What to watch
December 2027 (1)
FurmonertinibPhase 3EGFR, NSCLC (Advanced Non-small Cell Lung Cancer)
Est. primary completion 2027-12 · NCT06956001 · CT.gov ↗
What to watch
2028 (1)
October 2028 (1)
FurmonertinibPhase 3NSCLC, Adjuvant Treatment
Est. primary completion 2028-10-31 · NCT07010419 · CT.gov ↗
What to watch
2029 (3)
February 2029 (1)
FurmonertinibPhase 3Non-Small-Cell Lung Cancer, Metastatic Non-Small-Cell Lung Cancer, Advanced Non-Small-Cell Lung Cancer …
Est. primary completion 2029-02 · NCT07185997 · CT.gov ↗
What to watch
March 2029 (1)
FurmonertinibPhase 3NSCLC Patients With Brain Metastasis
Est. primary completion 2029-03 · NCT06970639 · CT.gov ↗
What to watch
September 2029 (1)
Glecirasib + SitneprotafibPhase 3Advanced Non-squamous Non-small-cell Lung Cancer, Metastatic Non-squamous Non Small Cell Lung Cancer
Est. primary completion 2029-09-30 · NCT06416410 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(1)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

6 October 2026Topline resultFurmonertinibArriVent reports the Phase 3 FURVENT trial of firmonertinib in first-line EGFR exon 20 NSCLC missed its primary PFS endpoint
ArriVent BioPharma · Source ↗

Financial reports

Quarterly & interim (1)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-Q3$190M———report ↗

Allist Pharmaceuticals reported revenue of $189.9M for Q3 2025.

Figures only: this period's report disclosed no narrative text

Annual history (3 years)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-FY$722M$75M——report ↗
View 2 more years
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2024-FY$495M$67M$80M—report ↗
2023-FY$286M———report ↗